These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11566616)

  • 1. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
    Yu K; Toral-Barza L; Discafani C; Zhang WG; Skotnicki J; Frost P; Gibbons JJ
    Endocr Relat Cancer; 2001 Sep; 8(3):249-58. PubMed ID: 11566616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin: a new molecular target for breast cancer.
    Mita MM; Mita A; Rowinsky EK
    Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Wu L; Birle DC; Tannock IF
    Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
    Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of mTOR and its inhibitory effect on cell proliferation and apoptosis of breast cancer cells.
    Cheng XF; Liu Q; Zhang XF; Zhao HD; Wang W; Chu AJ
    J Biol Regul Homeost Agents; 2015; 29(4):869-73. PubMed ID: 26753650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
    Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
    Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
    Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
    Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.
    Gera JF; Mellinghoff IK; Shi Y; Rettig MB; Tran C; Hsu JH; Sawyers CL; Lichtenstein AK
    J Biol Chem; 2004 Jan; 279(4):2737-46. PubMed ID: 14576155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
    Fung AS; Wu L; Tannock IF
    Clin Cancer Res; 2009 Sep; 15(17):5389-95. PubMed ID: 19706800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.
    Albert JM; Kim KW; Cao C; Lu B
    Mol Cancer Ther; 2006 May; 5(5):1183-9. PubMed ID: 16731750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.